Man Group plc Takes $3.17 Million Position in Omnicell, Inc. $OMCL

Man Group plc purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 76,339 shares of the company’s stock, valued at approximately $3,170,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in Omnicell during the second quarter valued at $26,000. Versant Capital Management Inc increased its stake in Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC raised its holdings in shares of Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell in the 4th quarter valued at about $58,000. Finally, Parkside Financial Bank & Trust boosted its position in shares of Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on OMCL. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Wells Fargo & Company decreased their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Piper Sandler restated an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Price Performance

OMCL opened at $35.16 on Tuesday. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.60 billion, a P/E ratio of 41.86, a PEG ratio of 0.83 and a beta of 0.98. The stock has a 50-day moving average price of $39.73 and a 200-day moving average price of $39.32. Omnicell, Inc. has a 12-month low of $29.06 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The company had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.Omnicell’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.